- Conditions
- Anxiety Disorders
- Interventions
- Quetiapine XR, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 66 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 14
- States / cities
- Fort Myers, Florida • Gainsville, Florida • Miami, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 5,496
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer, Radiation Pneumonitis
- Interventions
- Enalapril, placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Milwaukee, Wisconsin
- Conditions
- Alzheimer's Disease
- Interventions
- NGP 555
- Drug
- Lead sponsor
- NeuroGenetic Pharmaceuticals Inc
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Schizophrenia
- Interventions
- Iclepertin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Anaheim, California • Culver City, California • Los Angeles, California + 19 more
- Conditions
- Thrombocytopenia Associated With Liver Disease
- Interventions
- avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
- Conditions
- Alzheimer's Disease
- Interventions
- T-817MA, Placebo
- Drug
- Lead sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 28 more
- Conditions
- Colon Cancer, Precancerous Condition, Rectal Cancer
- Interventions
- oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 40 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more
- Conditions
- Adenocarcinoma
- Interventions
- Bevacizumab, Capecitabine, Cisplatin, Placebo, 5-fluorouracil
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
- Conditions
- Opioid Consumption, Postoperative
- Interventions
- Suzetrigine, Standard Care (in control arm)
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- COVID-19, SARS-CoV 2
- Interventions
- Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 7 more
- Conditions
- Prostatitis
- Interventions
- levofloxacin
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 36 more
- Conditions
- Phobic Disorders
- Interventions
- JNJ-42165279, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- La Jolla, California • Hartford, Connecticut • Orlando, Florida + 10 more
- Conditions
- Oral Leukoplakia
- Interventions
- Pioglitazone hydrochloride, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- A-002, varespladib methyl, Placebo
- Drug
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 5,189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
- Conditions
- Low Testosterone
- Interventions
- TAK-448, TAK-448 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
- Interventions
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
- Drug
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Northridge, California • Miami, Florida • Miami Lakes, Florida + 5 more
- Conditions
- Schizophrenia
- Interventions
- ACP-104, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 34
- States / cities
- Mesa, Arizona • Fresno, California • Greenbrae, California + 29 more
- Conditions
- Ureteral Calculi, Kidney Stones, Urolithiasis
- Interventions
- silodosin, placebo
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mission Hills, California + 24 more
- Conditions
- Treatment for Prevention of Chronic Migraine
- Interventions
- Erenumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 34
- States / cities
- La Jolla, California • Newport Beach, California • San Francisco, California + 30 more
- Conditions
- Heart Failure With Reduced Ejection Fraction, Congestion
- Interventions
- Ertugliflozin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York